03:58 AM EDT, 09/11/2025 (MT Newswires) -- Sanofi ( SNY ) said early Thursday that the US Food and Drug Administration granted fast-track designation to its therapeutic candidate, SAR402663, for neovascular age-related macular degeneration.

The company is currently evaluating the product in a phase 1/2 clinical study for the treatment of patients with the disease, which is an acquired progressive degeneration of the retina.

The fast-track designation process is intended to facilitate the development and expedite the review of the product, according to Sanofi ( SNY ).